Aurobindo Pharma Ltd
AUROPHARMAAurobindo Pharma Ltd
AUROPHARMAPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
23.04 | 2.72 | 0.32% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.31 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast from 26 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).
Peers
Compare with peersÂSun Pharmaceutical Industries Ltd
Cipla Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 13,999.90 | 15,030.45 | 16,568.15 | 19,721.57 | 23,290.38 | 28,404.97 | 23,891.87 | 25,145.97 | 29,559.25 | 30,425.32 | ||||||||||
Raw Materials | 6,254.98 | 6,743.46 | 7,235.26 | 9,388.19 | 9,837.09 | 10,632.68 | 9,323.60 | 11,702.94 | 13,549.07 | 23,589.99 | ||||||||||
Power & Fuel Cost | 419.26 | 437.14 | 470.95 | 556.79 | 587.68 | 589.28 | 626.86 | 842.63 | 826.03 | |||||||||||
Employee Cost | 1,542.62 | 1,767.76 | 2,130.84 | 2,584.87 | 3,219.18 | 3,535.02 | 3,450.92 | 3,522.25 | 3,922.94 | |||||||||||
Selling & Administrative Expenses | 1,684.89 | 1,969.34 | 2,270.45 | 2,363.93 | 3,162.20 | 3,638.42 | 3,332.28 | 3,705.32 | 3,973.53 | |||||||||||
Operating & Other expenses | 704.78 | 557.56 | 583.78 | 805.89 | 1,469.35 | 1,536.10 | 2,610.31 | 1,375.27 | 1,096.32 | |||||||||||
EBITDA | 3,393.37 | 3,555.19 | 3,876.87 | 4,021.90 | 5,014.88 | 8,473.47 | 4,547.90 | 3,997.56 | 6,191.36 | 6,835.33 | ||||||||||
Depreciation/Amortization | 392.37 | 427.63 | 557.97 | 667.95 | 966.71 | 1,055.39 | 1,126.52 | 1,244.58 | 1,521.66 | 1,599.28 | ||||||||||
PBIT | 3,001.00 | 3,127.56 | 3,318.90 | 3,353.95 | 4,048.17 | 7,418.08 | 3,421.38 | 2,752.98 | 4,669.70 | 5,236.05 | ||||||||||
Interest & Other Items | 256.70 | 66.72 | 77.72 | 262.60 | 305.13 | 74.49 | 48.64 | 140.48 | 289.71 | 344.20 | ||||||||||
PBT | 2,744.30 | 3,060.84 | 3,241.18 | 3,091.35 | 3,743.04 | 7,343.59 | 3,372.74 | 2,612.50 | 4,379.99 | 4,891.85 | ||||||||||
Taxes & Other Items | 719.21 | 759.18 | 818.01 | 726.62 | 897.90 | 2,008.75 | 724.59 | 685.00 | 1,207.02 | 1,370.41 | ||||||||||
Net Income | 2,025.09 | 2,301.66 | 2,423.17 | 2,364.73 | 2,845.14 | 5,334.84 | 2,648.15 | 1,927.50 | 3,172.97 | 3,521.44 | ||||||||||
EPS | 34.64 | 39.31 | 41.36 | 40.36 | 48.56 | 91.05 | 45.20 | 32.90 | 54.15 | 60.10 | ||||||||||
DPS | 2.50 | 2.50 | 2.50 | 2.50 | 3.00 | 4.00 | 9.00 | 7.50 | 4.50 | 4.50 | ||||||||||
Payout ratio | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 | 0.04 | 0.20 | 0.23 | 0.08 | 0.07 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Aurobindo Pharma Ltd | 25.57 | 2.72 | 0.32% |
Sun Pharmaceutical Industries Ltd | 45.19 | 6.45 | 0.75% |
Cipla Ltd | 31.37 | 4.82 | 0.81% |
Mankind Pharma Ltd | 56.85 | 11.36 | — |
Price Comparison
Compare AUROPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Aurobindo Pharma Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.3314% | Percentage of the fund’s portfolio invested in the stock 2.45% | Change in the portfolio weight of the stock over the last 3 months 0.26% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/79 (+4) |
Quant Mid Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.0668% | Percentage of the fund’s portfolio invested in the stock 9.18% | Change in the portfolio weight of the stock over the last 3 months 0.86% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/43 (-1) |
Mirae Asset Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7597% | Percentage of the fund’s portfolio invested in the stock 1.53% | Change in the portfolio weight of the stock over the last 3 months 0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/104 (+6) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
AUROPHARMA has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.32%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.23 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateFeb 20, 2024
Dividend/Share
₹1.50
Ex DateEx Date
Feb 20, 2024
Cash Dividend
Ex DateEx DateNov 20, 2023
Dividend/Share
₹3.00
Ex DateEx Date
Nov 20, 2023
Cash Dividend
Ex DateEx DateFeb 17, 2023
Dividend/Share
₹3.00
Ex DateEx Date
Feb 17, 2023
Cash Dividend
Ex DateEx DateJun 6, 2022
Dividend/Share
₹4.50
Ex DateEx Date
Jun 6, 2022
Cash Dividend
Ex DateEx DateFeb 18, 2022
Dividend/Share
₹1.50
Ex DateEx Date
Feb 18, 2022
Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
Aurobindo Pharma has completed the acquisition of balance 49% stake in its subsidiary, GLS Pharma on 25 October 2024. With this transaction, GLS Pharma has become a wholly owned subsidiary of the Company.Powered by Capital Market - Live
Aurobindo Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 1509.05, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 25134.8. The Sensex is at 82005.72, up 0.45%. Aurobindo Pharma Ltd has slipped around 0.62% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has slipped around 2.13% in last one month and is currently quoting at 23307.95, up 1.91% on the day. The volume in the stock stood at 3.63 lakh shares today, compared to the daily average of 13.57 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1519, up 1.41% on the day. Aurobindo Pharma Ltd is up 67.5% in last one year as compared to a 27.65% spurt in NIFTY and a 57.23% spurt in the Nifty Pharma index.The PE of the stock is 45.69 based on TTM earnings ending June 24.Powered by Capital Market - Live
Aurogen South Africa (Aurogen), a wholly owned step-down subsidiary of Aurobindo Pharma in South Africa, has entered into an agreement with Novabee Proprietary, to sell and dispose of the entire 50% shares held by Aurogen in Novagen. After the disposal of 50% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen.Powered by Capital Market - Live
Aurogen South Africa, (Aurogen) a wholly owned step-down subsidiary of Aurobindo Pharma in South Africa, has entered into an agreement with Rene Glyne Family trust to sell and dispose of the entire 24.5% shares held by Aurogen. After the disposal of 24.5% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen BBBEE Invest Co (Proprietary). Powered by Capital Market - Live
The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Keflet Tablets, 250 mg and 500 mg, of Eli Lilly and company. The product will be launched in Q3FY25. Aurobindo Pharma was granted Competitive Generic Therapy (CGT) designation for Cephalexin Tablets USP, 250 mg and 500 mg, and is eligible for 180 days of shared generic drug exclusivity. Cephalexin Tablets USP, 250 mg and 500 mg are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms. The drug maker now has a total of 523 ANDA approvals (506 Final approvals and 17 tentative approvals) from USFDA. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 79.5% jump in consolidated net profit to Rs 908.75 crore on a 17.1% rise in revenue from operations to Rs 7,580.15 crore in Q4 FY24 over Q4 FY23. Shares of Aurobindo Pharma rose 0.83% to Rs 1,450.55 on the BSE. Powered by Capital Market - Live
Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cephalexin Tablets USP, 250 mg and 500 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Keflet Tablets, 250 mg and 500 mg, of Eli Lilly and Company. Aurobindo Pharma was granted Competitive Generic Therapy (CGT) designation for Cephalexin Tablets USP, 250 mg and 500 mg, and is eligible for 180 days of shared generic drug exclusivity. The product is expected to be launched in Q3FY25. Cephalexin Tablets USP, 250 mg and 500 mg are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms. Powered by Capital Market - Live
The USFDA conducted inspection from 23 September to 27 September 2024.The inspection was closed with 10 observations. The firm stated that the observations are of procedural in nature and will be responded to within the stipulated time. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 61.1% surge in consolidated net profit to Rs 919.22 crore on a 9.8% rise in revenue from operations to Rs 7,457.65 crore in Q1 FY25 over Q1 FY24.Powered by Capital Market - Live
Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-II, an API manufacturing facility, of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Gaddapotharam Village IDA, Jinnaram Mandal, Sanga Reddy District, Telangana from 23-27 September 2024. The inspection closed with 10 observations. The observations are of procedural in nature and will be responded to within the stipulated time.Powered by Capital Market - Live
The United States Food and Drug Administration (USFDA) had conducted a pre-approval inspection (PAI) of the new injectable facility of Eugia Steriles, situated at Parawada Mandal, Anakapalli District in Andhra Pradesh, from 28 March 2024 to 5 April 2024. The unit has now received the EIR and the inspection is closed. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 61.1% surge in consolidated net profit to Rs 919.22 crore on a 9.8% rise in revenue from operations to Rs 7,457.65 crore in Q1 FY25 over Q1 FY24. Shares of Aurobindo Pharma fell 0.62% to currently trade at Rs 1,542.40 on the BSE. Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 8.43%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 8.99% to 7.84%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 6.06%, vs industry avg of 15.28%